Changing the Practice of Medicine
Popular
- CME/CE
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
1.00 credit
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Chan Y. Cheah, MBBS
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
CME/CE
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Clinical Practice
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Programs
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- MinuteCE®
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
2.00 credits 13 episodesDavid T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Michael Dolinger, MD, MBA
David T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Michael Dolinger, MD, MBA
David T. Rubin, MD
Florence Odufalu, MD
David T. Rubin, MD